As we transition from conference mode to earnings season some key questions remain unanswered. Tomorrow morning earnings season kicks off when Abbott reports full year and fourth quarter results. We have no doubt that Libre sales continue to progress well, that really isn’t an issue. The issue that’s on everyone’s mind is just when Libre2 will make it through the FDA.
Just to recap a little from JPM the company didn’t provide any additional clarity as to what the holdup is for Libre2. They confirmed the FDA has asked for and received additional information but no . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.